Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics.
作者： Yu-sheng Li , Qing Liu , Jian Tian , Hong-bo He , Wei Luo
DOI: 10.1016/J.AMJMS.2018.12.004
关键词:
摘要: In this review, we discuss the pathologic mechanism of angiogenesis process in osteosarcoma (OS) and therapeutic use inhibitors OS treatment. The activation endothelial cells by angiogenic factors leads to production proteolytic enzymes, which degrade extracellular matrix. degradation underlying basement membrane enables proliferate migrate surrounding tissue form new vessels. These vessels provide cancer with oxygen nutrition play an important role cell survival metastasis. Thus, antiangiogenic therapies might be interesting approach therapeutics.
sci-hub.st 参考文章(92)
Giulia Ottaviani, Norman Jaffe, The etiology of osteosarcoma. Cancer treatment and research. ,vol. 152, pp. 15- 32 ,(2009) , 10.1007/978-1-4419-0284-9_2
Giulia Ottaviani, Norman Jaffe, The Epidemiology of Osteosarcoma Cancer treatment and research. ,vol. 152, pp. 3- 13 ,(2009) , 10.1007/978-1-4419-0284-9_1
Jinfeng Ma, Hai Huang, Zenggang Han, Changzheng Zhu, Bin Yue, RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance BioMed Research International. ,vol. 2015, pp. 147468- 147468 ,(2015) , 10.1155/2015/147468
Aude I. Ségaliny, Amel Mohamadi, Blandine Dizier, Anna Lokajczyk, Régis Brion, Rachel Lanel, Jérôme Amiaud, Céline Charrier, Catherine Boisson-Vidal, Dominique Heymann, Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. International Journal of Cancer. ,vol. 137, pp. 73- 85 ,(2015) , 10.1002/IJC.29376
M Hall, C Gourley, I McNeish, J Ledermann, M Gore, G Jayson, T Perren, G Rustin, S Kaye, Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer. ,vol. 108, pp. 250- 258 ,(2013) , 10.1038/BJC.2012.541
Ga Bin Park, Dae-Jin Kim, Yeong-Seok Kim, Hyun-Kyung Lee, Chang Wan Kim, Dae Young Hur, None, Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents. International Journal of Oncology. ,vol. 46, pp. 185- 194 ,(2015) , 10.3892/IJO.2014.2721
Jin Wu, Xinyu Wu, Daixing Zhong, Wenliang Zhai, Zhenqi Ding, Yong Zhou, Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling International Journal of Molecular Sciences. ,vol. 13, pp. 12573- 12583 ,(2012) , 10.3390/IJMS131012573
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, Meredith K. Chuk, Eva Dombi, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Nalini Jayaprakash, Marcelo Marotti, Kathryn H. Brown, Barbara Wenrich, Peter C. Adamson, Brigitte C. Widemann, Frank M. Balis, A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors Journal of Clinical Oncology. ,vol. 28, pp. 5174- 5181 ,(2010) , 10.1200/JCO.2010.30.9674
Lisa Mirabello, Rebecca J. Troisi, Sharon A. Savage, Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program Cancer. ,vol. 115, pp. 1531- 1543 ,(2009) , 10.1002/CNCR.24121
Ruipeng Song, Ke Tian, Weidong Wang, Limin Wang, P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway International Journal of Surgery. ,vol. 20, pp. 80- 87 ,(2015) , 10.1016/J.IJSU.2015.04.050